Interagency Patent Coordination and Improvement Act of 2022

The Interagency Patent Coordination and Improvement Act of 2022 establishes a formal task force to improve communication and data sharing between the U.S. Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA). This collaboration is designed to ensure that patent examiners have access to relevant information from the FDA when reviewing applications for human drugs and biological products.

For the average citizen, this bill aims to increase the accuracy and integrity of the pharmaceutical patent process. By streamlining how these two agencies share information, the legislation seeks to prevent the issuance of invalid patents, which can help promote fair competition in the marketplace and potentially lead to more timely access to lower-cost generic medications.